Big Cheese Ventures
Vienna, Austria2
1M
2
0.67
- Areas of investment
Investor highlights
- Industry generalist
- Yes
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Rounds per year
- 0.67
- Investments by industry
- Software (1)
- Legal Tech (1)
- Internet (1)
- Legal (1)
- SaaS (1) Show 3 more
- Investments by region
- Austria (2)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 3
- Avg. valuation at time of investment
- 2M
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Froots | 18 Jun 2024 | Asset Management, FinTech, Wealth Management | Seed | 2M |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| EpiBiologics , a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, | Aug 1, 2026 | Biotechnology, Protein Degradation | - | 107000000 USD | EpiBiologics |
| TRexBio , a San Francisco, CA-based clinical-stage biotechnology company | Jan 27, 2026 | Biotechnology, Computational Biology, Immunoregulatory Medicines | - | 50000000 USD | CA-based clinical-stage biotechnology company, a San Francisco |
| Alveus Therapeutics , a Philadelphia, PA-based clinical-stage biotechnology company | Aug 1, 2025 | Biotechnology, Therapies for Metabolic Diseases, Therapies for Obesity | - | 160000000 USD | PA-based clinical-stage biotechnology company, a Philadelphia |
| MapLight Therapeutics | Jul 28, 2025 | Biopharmaceutical, Central Nervous System Disorders | - | 372500000 USD |  Redwood City, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.